The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review
Abstract
BACKGROUND: New oral anticoagulants (NOACs), including direct thrombin inhibitors (DTIs) and factor Xa (FXa) inhibitors, are emerging alternatives for prophylaxis and treatment of atrial fibrillation (AF) and venous thromboembolism (VTE). PURPOSE: To compare the benefits and harms of NOACs versus warfarin for AF and VTE. DATA SOURCES: MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews from January 2001 through July 2012; U.S. Food and Drug Administration (FDA) database for adverse event reports. STUDY SELECTION: English-language, randomized, controlled trials (RCTs) comparing NOACs with warfarin for management of AF or VTE and observational studies and FDA reports on adverse effects. DATA EXTRACTION: Two independent reviewers abstracted data and rated study quality and strength of evidence. DATA SYNTHESIS: Six good-quality RCTs compared NOACs (2 DTI studies, 4 FXa inhibitor studies) with warfarin. In AF, NOACs decreased all-cause mortality (risk ratio [RR], 0.88 [95% CI, 0.82 to 0.96]); in VTE, NOACs did not differ for mortality or VTE outcomes. Across indications, adverse effects of NOACs compared with warfarin were fatal bleeding (RR, 0.60 [CI, 0.46 to 0.77]), major bleeding (RR, 0.80 [CI, 0.63 to 1.01]), gastrointestinal bleeding (RR, 1.30 [CI, 0.97 to 1.73]), and discontinuation due to adverse events (RR, 1.23 [CI, 1.05 to 1.44]). Subgroup analyses suggest a higher risk for myocardial infarction with DTIs than with FXa inhibitors. Bleeding risk for NOACs may be increased in persons older than 75 years or those receiving warfarin who have good control. LIMITATION: There were no head-to-head comparisons of NOACs and limited data on harms. CONCLUSION: New oral anticoagulants are a viable option for patients receiving long-term anticoagulation. Treatment benefits compared with warfarin are small and vary depending on the control achieved by warfarin treatment. PRIMARY FUNDING SOURCE: Department of Veterans Affairs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
GRADE guidelines 6. Rating the quality of evidence—imprecision
Guyatt, G. H., Oxman, A. D., Kunz, R., Brozek, J., Alonso-Coello, P., Rind, D., Devereaux, P. J., Montori, V. M., Freyschuss, B., Vist, G., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.01.012 · Cited by 2,693
Self-citationBüller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Eikelboom, J. W., Wallentin, L., Connolly, S. J., Ezekowitz, M., Healey, J. S., Oldgren, J., Yang, S., Alings, M., Kaatz, S., Hohnloser, S. H., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.004747 · Cited by 1,081
Newly identified events in the RE-LY trial
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1007378 · Cited by 688
Carrier, M., Le Gal, G., Wells, P. S., & Rodger, M. A. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-9-201005040-00008 · Cited by 473
Research works printed but not linked: 53
- 10.1001/archinte.167.13.1414 · DOI · Paper page
- 10.1001/archinte.1994.00420130036007 · DOI · Paper page
- 10.1378/chest.119.1_suppl.220S · DOI · Paper page
- 10.1161/01.CIR.89.2.635 · DOI · Paper page
- 10.1093/oxfordjournals.eurheartj.a060739 · DOI · Paper page
- 1998, Lancet, 351, 233, 10.1016/S0140-6736(97)11475-1 · DOI · Paper page
- 10.5694/j.1326-5377.2004.tb06407.x · DOI · Paper page
- 10.1016/j.amjmed.2011.01.016 · DOI
- 10.1378/chest.08-0670 · DOI · Paper page
- 10.1007/s11239-008-0211-4 · doi:10.1007/s11239-008-0211-4
- 10.1136/hrt.2004.042465 · DOI · Paper page
- 10.1111/j.1742-1241.2010.02351.x · DOI
- 10.1146/annurev-pharmtox-010611-134633 · DOI
- 10.1161/CIRCULATIONAHA.111.030148 · DOI
- 10.1016/S1474-4422(10)70275-1 · doi:10.1016/s1474-4422(10)70275-1
- 10.1161/CIRCULATIONAHA.109.853119 · DOI · Paper page
- 10.1093/eurheartj/sun040 · doi:10.1093/eurheartj/sun040
- 10.1001/archinte.166.12.1269 · DOI
- Akl EA, 2008, Cochrane Database Syst Rev, CD006650
- 10.1111/j.1538-7836.2007.02847.x · DOI
- 10.1016/j.amjmed.2010.01.031 · DOI
- 10.1001/archinternmed.2011.1666 · DOI · Paper page
- 10.1016/0197-2456(86)90046-2 · DOI · Paper page
- 10.1002/sim.1186 · DOI · Paper page
- 10.1378/chest.11-2290 · DOI · Paper page
- 10.1056/NEJMoa0906598 · DOI · Paper page
- 10.1016/S1474-4422(10)70274-X · DOI · Paper page
- 10.1016/S0140-6736(10)61194-4 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.111.055970 · DOI · Paper page
- 10.7326/0003-4819-155-10-201111150-00004 · DOI · Paper page
- 10.1159/000334578 · DOI
- 10.1001/archinternmed.2011.314 · DOI · Paper page
- Moore CH, 2011, Am J Emerg Med
- 10.1002/j.1875-9114.2012.01036.x · DOI
- Fellows SE, 2012, J Emerg Med
- 10.3109/15563650.2012.705290 · DOI
- 10.1159/000319886 · DOI
- 10.1160/TH11-01-0042 · DOI
- 10.1056/NEJMoa0905561 · DOI · Paper page
- 10.1016/j.amjcard.2007.06.034 · DOI · Paper page
- 10.1093/eurheartj/ehr113 · DOI · Paper page
- 10.1111/j.1538-7836.2007.02748.x · DOI · Paper page
- 10.1016/S0140-6736(07)61445-7 · DOI · Paper page
- 10.1160/TH10-10-0679 · DOI · Paper page
- 10.1016/j.amjcard.2012.03.049 · DOI · Paper page
- 10.1345/aph.1P644 · DOI
- 10.1177/0003319711422808 · DOI
- 10.1161/CIR.0b013e31820f14c0 · DOI · Paper page
- Wallentin L, 2010, Circulation, 120, 2158
- 10.4330/wjc.v3.i11.351 · DOI
- 10.1161/CIRCULATIONAHA.110.985655 · DOI · Paper page
- 10.1161/CIRCOUTCOMES.111.960591 · DOI
- 10.1136/bmj.b1147 · DOI · Paper page
Cited by
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
Self-citationCancer-associated venous thromboembolism: Burden, mechanisms, and management
Ay, C., Pabinger, I., & Cohen, A. T. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-08-0615 · Cited by 496
Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism
Kearon, C., & Akl, E. A. (2014) · Blood · doi:10.1182/blood-2013-12-512681 · Cited by 279
Metadata
- Authors
- Adam, S. S., McDuffie, J. R., Ortel, T. L., & Williams, J. W.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2012-12-04
- Volume
- 157
- Issue
- 11
- Pages
- 796-807
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2095151586
- Cited by
- 194
- References
- 10
- FWCI
- 17.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review. https://app.cochat.ai/papers/10.7326/0003-4819-157-10-201211200-00532
- The paper
- Adam, S. S., McDuffie, J. R., Ortel, T. L., & Williams, J. W. (2012). Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-157-10-201211200-00532
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.